Reporting, Evaluating, Preventing and Treating the Cardiotoxicity Induced by Anticancer Drugs During a Specific Cardio-oncology Consult and Follow up in Routine Care (NEOCARDIO)

Groupe Hospitalier Pitie-Salpetriere

Status

Enrolling

Conditions

Cardiovascular Insufficiency

Vascular Disorder

Metabolic Disorder

Cardiovascular Complication

Cardiac Disorder

Cardiac Complication

Cardiac Insufficiency

Oncologic Complications

Treatments

Drug: Anti-Cancer Agents

Study type

Observational

Funder types

Other

Identifiers

NCT03882580

CIC1421-19-05

Details and patient eligibility

About

Several Drugs used in routine care in oncology induce rare but often severe or fatal cardiovascular or metabolic side effects. This study will investigate, evaluate, report and treat the cardiovascular side effects of anticancer drugs, through a specific cardiovascular routine checkup and follow-up taking place in several Cardio-oncology programs throughout France. The different including centers will be: Assistance Publique - Hôpitaux de Paris (APHP.6: Pitié-Salpétrière, Saint Antoine and Tenon's hospitals, Paris, France).

Full description

Several anticancer and supportive care drugs used in oncology have an impact on the cardiovascular and metabolic systems, leading to a wide range of cardiovascular and metabolic disorders and side effects. Those are poorly described, due to the evolution of the anticancer pharmacopeia, and recent recognition of these adverse events. This study will investigate the potential benefits of a specialized cardio-oncology check-up and follow-up in this context.

Enrollment

5,000 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria